Elasmogen: Funding, Investors & Team (Sep 2026)
Elasmogen is developing soloMERs: fully humanized, next generation, single chain therapeutics for auto-inflammatory diseases, ophthalmology, oncology and intracellular delivery. soloMERs are proprietary humanized clinical candidates derived from VNARS (variable new-antigen receptors) which exist naturally in sharks as high affinity binding domains. With a different ancestral origin from antibodies this example of 400 million year old convergent evolution places VNARs outside of the complex patent landscape that describes and protects antibody drug discovery and has produced the smallest (9% of the size of an antibody) and most robust naturally occurring binding domain. Elasmogen is unique in its capacity to isolate and develop soloMERs, with a multi-layered IP position covering the platform, products and process including an exclusive license to over 20 patents granted in the US, Europe and other territories together with the entire know-how and VNAR pipeline/product output from the Scottish Biologics Facility, University of Aberdeen.
Elasmogen has raised $9.9M across 1 funding round on record, the most recent an undisclosed round of $9.9M announced in May 2022.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Elasmogen Company Profile and Key Stats
Latest funding round on record: May 2022.
Elasmogen Funding Rounds
Elasmogen Founders and Leadership Team
Contact details for the Elasmogen team: 1 of 1 has an email address on file.
Start 14-day free trial →Elasmogen Funding Compared to Other Health Care Startups
Elasmogen's latest round of $9.9M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Elasmogen in Health Care and Aberdeen
Companies Similar to Elasmogen
Renata Medical develops purposeful medical devices for unmet pediatric needs.
Leo Cancer Care provides a streamlined and effective treatment method that empowers patients and instills…
Neubond develops wearable devices for stroke mobility rehabilitation. These devices provide autonomous…
Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.
Nebu-Flow is a manufacturer of the next generation of inhaled drugs for patients with respiratory disorders.…
iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial…
Innovative medical gadgets are created by Creo Medical Limited, situated in Chepstow, South Wales. With a…
TympaHealth has developed the world's first ear and hearing health assessment system. The Tympa system…
NEX Health Intelligence (NEX) is a health-tech business that develops AI-powered software for hospitals to…
Infex Therapeutics acquire, develop and license drugs to treat pandemic infections.
Asterix Health is the workforce solution for modern healthcare.
Gloucester Rugby is a professional English rugby union club that gives up to date with all the information…
Elasmogen Funding FAQs
What does Elasmogen do?
Elasmogen is developing soloMERs: fully humanized, next generation, single chain therapeutics for auto-inflammatory diseases, ophthalmology, oncology and intracellular delivery. soloMERs are proprietary humanized clinical candidates derived from VNARS (variable new-antigen receptors) which exist naturally in sharks as high affinity binding domains. With a different ancestral origin from antibodies this example of 400 million year old convergent evolution places VNARs outside of the complex patent landscape that describes and protects antibody drug discovery and has produced the smallest (9% of the size of an antibody) and most robust naturally occurring binding domain. Elasmogen is unique in its capacity to isolate and develop soloMERs, with a multi-layered IP position covering the platform, products and process including an exclusive license to over 20 patents granted in the US, Europe and other territories together with the entire know-how and VNAR pipeline/product output from the Scottish Biologics Facility, University of Aberdeen.
How much funding has Elasmogen raised?
Elasmogen has raised $9.9M across 1 round on record. The most recent is an undisclosed round of $9.9M announced in May 2022.
When did Elasmogen last raise funding?
Elasmogen's most recent funding round on record is an undisclosed round of $9.9M, announced in May 2022.
Who is the CEO of Elasmogen?
Caroline Barelle is listed as CEO at Elasmogen.
Where is Elasmogen headquartered?
Elasmogen is based in Aberdeen, United Kingdom.
How many employees does Elasmogen have?
Elasmogen is in the 11-50 employee band.
How does Elasmogen's funding compare to other Health Care startups?
Elasmogen's latest round of $9.9M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Elasmogen Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Elasmogen is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.